20 CHAPTER 1 59. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16(13):1324-1334. (In English). DOI: 10.1016/S1470-2045(15)00188-6. 60. Massard C, Michiels S, Ferte C, et al. High-Throughput Genomics and Clinical Outcome in Hardto-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 2017;7(6):586-595. (In English). DOI: 10.1158/2159-8290.Cd-16-1396. 61. Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine 2019;25(5):751-+. (In English). DOI: 10.1038/s41591019-0424-4. 62. Rothwell DG, Ayub M, Cook N, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nature Medicine 2019;25(5):738-+. (In English). DOI: 10.1038/s41591019-0380-z. 63. Schwaederle M, Parker BA, Schwab RB, et al. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther 2016;15(4):743-752. (In English). DOI: 10.1158/15357163.Mct-15-0795. 64. Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nature Medicine 2019;25(5):744-+. (In English). DOI: 10.1038/s41591-019-0407-5. 65. Stockley TL, Oza AM, Berman HK, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med 2016;8 (In English). DOI: ARTN 109 10.1186/s13073-016-0364-2. 66. Tredan O, Wang Q, Pissaloux D, et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol 2019;30(5):757-765. (In English). DOI: 10.1093/annonc/mdz080. 67. Tsimberidou AM, Hong DS, Ye Y, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. Jco Precis Oncol 2017;1 (In English). DOI: Doi 10.1200/Po.17.00002. 68. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. Clinical Cancer Research 2012;18(22):63736383. (In English). DOI: 10.1158/1078-0432.Ccr-12-1627. 69. Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot Study Using Molecular Profiling of Patients’ Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. Journal of Clinical Oncology 2010;28(33):4877-4882. (In English). DOI: 10.1200/Jco.2009.26.5983. 70. Wheler JJ, Janku F, Naing A, et al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research 2016;76(13):3690-3701. (In English). DOI: 10.1158/0008-5472. Can-15-3043.
RkJQdWJsaXNoZXIy MTk4NDMw